Is fibrinogen a marker of inflammation in coronary artery disease?

Hellenic Journal of Cardiology

Volumn 51, Issue 1, 2010, Pages 1-9

  Papageorgiou, Nikolaos ^a   Tousoulis, Dimitris ^a   Siasos, Gerasimos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute phase proteins; Atherosclerosis; Inflammatory process; Myocardial infarction

Indexed keywords

ACUTE PHASE PROTEIN; FIBRIN; FIBRINOGEN; FIBRONECTIN;

ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DNA POLYMORPHISM; EDITORIAL; ENDOTHELIAL DYSFUNCTION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENOTYPE; HEART INFARCTION; HUMAN; PROTEIN FUNCTION; STROKE;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FIBRINOGEN; HUMANS; INFLAMMATION;

EID: 77349105793     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (49)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
2. Economou E, Tousoulis D, Katinioti A, et al. Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int J Cardiol. 2001; 80: 55-60.
3. Tousoulis D, Davies GJ, Asimakopoulos G, et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol. 2001; 24: 301-304.
4. Sanidas EA, Vavuranakis M, Papaioannou TG, et al. Study of atheromatous plaque using intravascular ultrasound. Hellenic J Cardiol. 2008; 49: 415-421.
5. Vogiatzi G, Tousoulis D, Stefanadis C. The role of oxidative stress in atherosclerosis. Hellenic J Cardiol. 2009; 50: 402-409.
6. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
7. Kampoli A-M, Tousoulis D, Antoniades C, Siasos G, Stefanadis C. Biomarkers of premature atherosclerosis. Trends Mol Med. 2009; 15: 323-332.
8. Cook NS, Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci. 1990; 11: 444-451.
9. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol. 1986; 15: 355-370.
10. Naito M, Funaki C, Hayashi T, et al. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis. 1992; 96: 227-234.
11. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 1993; 126: 1299-1304.
12. Tousoulis D, Davies G, Ambrose J, Tentolouris C, Stefanadis C, Toutouzas P. Effects of lipids on thrombotic mechanisms in atherosclerosis. Int J Cardiol. 2002; 86: 239-247.
13. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003; 89: 993-997.
14. Wilhelmsen L, Svδrdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311: 501-505.
15. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987; 258: 1183-1186.
16. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990; 120: 672-676.
17. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995; 332: 635-641.
18. Rana JS, Cote M, Desprιs J-P, et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. Heart. 2009; 95: 1682-1687.
19. Acevedo M, Foody JAM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J. 2002; 143: 277-282.
20. Robinson DM, Schwahn C, Alte D, John U, Felix SB, Völzke H. Plasma fibrinogen levels are associated with a strong family history of myocardial infarction. Blood Coagul Fibrinolysis. 2004; 15: 497-502.
21. Germing A, von Dryander S, Machraoui A, et al. Hyperfibrinogenemia increases the risk of cardiac events after coronary artery stenting. Heart Vessels. 2000; 15: 263-267.
22. Shojaie M, Pourahmad M, Eshraghian A, Izadi HR, Naghshvar F. Fibrinogen as a risk factor for premature myocardial infarction in Iranian patients: a case control study. Vasc Health Risk Manag. 2009; 5: 673-676.
23. Pineda J, Marνn F, Marco P, et al. Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol. 2009; 136: 222-225.
24. Green D, Chan C, Kang J, et al. Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA Study. J Thromb Haemost. 2009. [Epub ahead of print]
25. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. Coron Artery Dis. 2009; 20: 15-20.
26. Levenson J, Giral P, Megnien JL, Gariepy J, Plainfosse MC, Simon A. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. Arterioscler Thromb Vasc Biol. 1997; 17: 45-50.
27. Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis. 2007; 195: e126-134.
28. Gil M, Zarebiński M, Adamus J. Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina. Int J Cardiol. 2002; 83: 43-46.
29. Cremer P, Nagel D, Seidel D, van de Loo JC, Kienast J. Considerations about plasma fibrinogen concentration and the cardiovascular risk: combined evidence from the GRIPS and ECAT studies. Goettingen Risk Incidence and Prevalence Study. European Concerted Action on Thrombosis and Disabilities. Am J Cardiol. 1996; 78: 380-381.
30. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994; 24: 444-453.
31. Lawlor DA, Smith GD, Rumley A, Lowe GDO, Ebrahim S. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women's Heart and Health Study. Thromb Haemost. 2005; 93: 955-963.
32. Hartmann M, von Birgelen C, Mintz GS, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol. 2006; 48: 446-452.
33. Cavusoglu Y, Gorenek B, Alpsoy S, Unalir A, Ata N, Timuralp B. Evaluation of C-reactive protein, fibrinogen and antithrombin-III as risk factors for coronary artery disease. Isr Med Assoc J. 2001; 3: 13-16.
34. Tousoulis D, Davies G, Tentolouris C, Bosinakou E, Toutouzas P. Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction. Am J Cardiol. 1998; 81: 497-500.
35. Sjoländ H, Tengborn L, Stensdotter L, Herlitz J. Lack of very strong association between pre-treatment fibrinogen and PAI-1 with long-term mortality after coronary bypass surgery. Cardiology. 2007; 108: 82-89.
36. Green F, Hamsten A, Blombäck M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost. 1993; 70: 915-920.
37. van 't Hooft FM, von Bahr SJ, Silveira A, Iliadou A, Eriksson P, Hamsten A. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol. 1999; 19: 3063-3070.
38. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455->A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest. 1997; 99: 3034-3039.
39. Carter AM, Mansfield MW, Stickland MH, Grant PJ. Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care. 1996; 19: 1265-1268.
40. Papageorgiou N, Tousoulis D, Antoniades C, et al. The impact of the genetic polymorphism G455A on fibrinogen b-chain gene on patients with coronary artery disease and healthy individuals: effects on inflammatory and thrombotic process. Eur Heart J. 2009 Suppl (I); 30: 636.
41. Tousoulis D, Koumallos N, Antoniades C, et al. Genetic polymorphism on type 2 receptor of angiotensin II, modifies cardiovascular risk and systemic inflammation in hypertensive males. Am J Hypertens. 2009. [Epub ahead of print].
42. Boekholdt SM, Sandhu MS, Wareham NJ, Luben R, Reitsma PH, Khaw K-T. Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost. 2006; 4: 2204-2209.
43. Mannila MN, Lovely RS, Kazmierczak SC, et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost. 2007; 5: 766-773.
44. Sun AJ, Ma HL, Chen XY, et al. Association of fibrinogen and fibrinogen gene beta148 and beta854 polymorphisms with coronary heart disease. Cardiology. 2008; 111: 167-170.
45. Doggen CJ, Bertina RM, Cats VM, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol. 2000; 110: 935-938.
46. Blake GJ, Schmitz C, Lindpaintner K, Ridker PM. Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J. 2001; 22: 2262-2266.
47. Leander K, Wiman B, Hallqvist J, Falk G, De Faire U. The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women. J Intern Med. 2002; 252: 332-341.
48. Chen XC, Xu MT, Jin LZ, Chen J, Chen WQ. Association of beta-fibrinogen gene -148C/T and -455G/A polymorphisms and coronary artery disease in Chinese population: a meta analysis. Sci China C Life Sci. 2008; 51: 814-820.
49. Kardys I, Uitterlinden AG, Hofman A, Witteman JCM, de Maat MPM. Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: the Rotterdam Study. Thromb Haemost. 2007; 97: 288-295.